STUDY OBJECTIVE: to ascertain whether measuring the proliferative response of bronchoalveolar lymphocytes to beryllium salts is useful for diagnosing chronic beryllium disease. DESIGN: prospective case series compared to normal volunteers and patients with sarcoidosis. SETTING: university referral center. PATIENTS: twenty-three consecutive beryllium workers were evaluated. Fourteen had chronic beryllium disease diagnosed on the basis of histologic evidence of a progressive pulmonary granulomatosis. Four had biopsy evidence of non-beryllium disease. Three had probable chronic beryllium disease but did not have lung biopsies. Two did not have biopsies and had basilar fibrosis on chest roentgenogram suggestive of non-beryllium lung disease. These patients were compared with 6 normal volunteers and 16 patients with sarcoidosis. MEASUREMENTS AND MAIN RESULTS: bronchoalveolar lavage was done and the proliferative response of the lung cells to two beryllium salts was tested. A positive proliferative test was defined as a stimulation index of more than five on two determinations. The sensitivity of this test was 100% in the 14 patients with definite chronic beryllium disease. The specificity of the test was also 100% among the normal volunteers and the 16 patients with sarcoidosis. The test was positive in none of the four patients with biopsy evidence of non-beryllium disease, none out of two patients with lower lobe fibrosis suggestive of non-beryllium disease, and all of three patients with probable chronic beryllium lung disease. CONCLUSIONS: the proliferative response of bronchoalveolar lymphocytes to beryllium appears to be a useful test for chronic beryllium disease.
STUDY OBJECTIVE: to ascertain whether measuring the proliferative response of bronchoalveolar lymphocytes to beryllium salts is useful for diagnosing chronic beryllium disease. DESIGN: prospective case series compared to normal volunteers and patients with sarcoidosis. SETTING: university referral center. PATIENTS: twenty-three consecutive beryllium workers were evaluated. Fourteen had chronic beryllium disease diagnosed on the basis of histologic evidence of a progressive pulmonary granulomatosis. Four had biopsy evidence of non-beryllium disease. Three had probable chronic beryllium disease but did not have lung biopsies. Two did not have biopsies and had basilar fibrosis on chest roentgenogram suggestive of non-berylliumlung disease. These patients were compared with 6 normal volunteers and 16 patients with sarcoidosis. MEASUREMENTS AND MAIN RESULTS: bronchoalveolar lavage was done and the proliferative response of the lung cells to two beryllium salts was tested. A positive proliferative test was defined as a stimulation index of more than five on two determinations. The sensitivity of this test was 100% in the 14 patients with definite chronic beryllium disease. The specificity of the test was also 100% among the normal volunteers and the 16 patients with sarcoidosis. The test was positive in none of the four patients with biopsy evidence of non-beryllium disease, none out of two patients with lower lobe fibrosis suggestive of non-beryllium disease, and all of three patients with probable chronic berylliumlung disease. CONCLUSIONS: the proliferative response of bronchoalveolar lymphocytes to beryllium appears to be a useful test for chronic beryllium disease.
Authors: Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin Journal: J Clin Invest Date: 2003-09 Impact factor: 14.808
Authors: Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin Journal: J Clin Invest Date: 2005-09-08 Impact factor: 14.808
Authors: Brent E Palmer; Douglas G Mack; Allison K Martin; May Gillespie; Margaret M Mroz; Lisa A Maier; Andrew P Fontenot Journal: J Immunol Date: 2008-02-15 Impact factor: 5.422
Authors: Shaodong Dai; Guinevere A Murphy; Frances Crawford; Douglas G Mack; Michael T Falta; Philippa Marrack; John W Kappler; Andrew P Fontenot Journal: Proc Natl Acad Sci U S A Date: 2010-03-31 Impact factor: 11.205
Authors: Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot Journal: Am J Respir Crit Care Med Date: 2010-03-18 Impact factor: 21.405
Authors: Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day Journal: Am J Respir Cell Mol Biol Date: 2009-11-09 Impact factor: 6.914
Authors: Brian C Tooker; Stephen M Brindley; Marina L Chiarappa-Zucca; Kenneth W Turteltaub; Lee S Newman Journal: J Immunotoxicol Date: 2014-06-16 Impact factor: 3.000